10/540,616A Yong Chu 10-9-2006

$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:35:35 ON 09 OCT 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:35:50 ON 09 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 OCT 2006 HIGHEST RN 909865-12-9
DICTIONARY FILE UPDATES: 8 OCT 2006 HIGHEST RN 909865-12-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10540616\10540616G.str





chain nodes :
7 8 9 11 12
ring nodes :
1 2 3 4 5 6 10 13 14 15 16 17 18 19 20 21
chain bonds :
5-7 7-8 8-9 8-11 9-10 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-13 10-17 13-14 13-21 14-15 15-16 15-19 16-17
17-18 18-20 19-20 20-21
exact/norm bonds :
8-9 8-11 9-10 9-12 10-13 10-17 13-14 13-21 14-15 15-16 15-19 16-17 17-18
18-20 19-20 20-21
exact bonds :
5-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:36:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 466 TO ITERATE

100.0% PROCESSED 466 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8025 TO 10615
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:36:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8996 TO ITERATE

100.0% PROCESSED 8996 ITERATIONS 116 ANSWERS
SEARCH TIME: 00.00.01

L3 116 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 14:36:38 ON 09 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Oct 2006 VOL 145 ISS 16
FILE LAST UPDATED: 8 Oct 2006 (20061008/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 17 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:657359 CAPLUS Full-text
DOCUMENT NUMBER: 145:110213
TITLE: Metabolic stabilization of substituted adamantane
INVENTOR(S): Rohde, Jeffrey J.; Pan, Liping; Pliushchev, Marina;

Link, James T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006148871	A1	20060706	US 2006-325956		20060105
PRIORITY APPLN. INFO.:			US 2005-641676P	P	20050105

OTHER SOURCE(S): MARPAT 145:110213

AB The present invention is directed to the method of increasing the metabolic stability of adamantane contg. compds. that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 (11-beta-HSD-1) enzyme. The stability is achieved by substitutions of the adamantane ring. For example, soln. of 2-adamantanamine hydrochloride 38 mg, 2-phenylisobutyric acid 30 mg, , and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate 65 mg in N,N-dimethylacetamide 2 mL and DIEA 80 .mu.L, was stirred for 16 h at 23 0C to get N-2-adamantyl-2-methyl-2- phenylpropanamide.

IT 717889-77-5P 717889-79-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(metabolic stabilization of substituted adamantane)

RN 717889-77-5 CAPLUS
CN Benzeneacetamide, 4-chloro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-79-7 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:657188 CAPLUS Full-text
DOCUMENT NUMBER: 145:124215
TITLE: Preparation of N-adamantane carboxamide derivatives as

inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

INVENTOR(S): Rohde, Jeffrey J.; Shuai, Qi; Link, James T.; Patel, Jyoti R.; Dinges, Jurgen; Sorensen, Bryan K.; Yong, Hong; Yeh, Vince S.; Kurukulasuriya, Ravi

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 58 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006149070	A1	20060706	US 2006-326277	20060105
WO 2006074330	A2	20060713	WO 2006-US402	20060105

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-641496P P 20050105
US 2006-326277 A 20060105

OTHER SOURCE(S): MARPAT 145:124215

GI



I



II

AB Title compds. I [A1-4 one of which = alkyl-NH-alkyl, alkylcarbonyl, cycloalkyl, etc. with the remaining of A = H, alkyl, aryl, etc.; R1 = H or

alkyl; R2 = H, alkyl or cycloalkyl; R3 = substituted acetyl with CO attached directly to N forming amide bond], and their pharmaceutically acceptable salts, are prepd. and disclosed as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Thus, e.g., II was prepd. by amination of the corresponding acid (prepn. given). The present invention further relates to the use of inhibitors of 11-beta- hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action. In assays for inhibition of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, I demonstrated IC50 values ranging from 16-104 nM.

IT 717889-79-7P 897394-74-0P 897394-78-4P
897394-88-6P 897394-92-2P 897394-94-4P
897395-00-5P 897395-01-6P 897395-02-7P
897395-03-8P 897395-05-0P 897395-10-7P
897395-12-9P 897395-18-5P 897395-19-6P
897395-21-0P 897395-23-2P 897395-26-5P
897395-29-8P 897395-37-8P 897395-38-9P
897395-39-0P 897395-43-6P 897395-44-7P
897395-45-8P 897395-46-9P 897395-47-0P
897395-49-2P 897395-51-6P 897395-52-7P
897395-54-9P 897395-56-1P 897395-57-2P
897395-58-3P 897395-59-4P 897395-60-7P
897395-62-9P 897395-65-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-adamantane carboxamide derivs. as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme)

RN 717889-79-7 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 897394-74-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897394-78-4 CAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-(4-chlorophenyl)-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897394-88-6 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-(4-pyridinyl)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897394-92-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-[5-(trifluoromethyl)-2-pyridinyl]phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897394-94-4 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-(4-bromophenyl)-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-00-5 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-2-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-01-6 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-(3-bromophenyl)-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-02-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-03-8 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-(3-pyridinyl)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-05-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-(1H-pyrazol-4-yl)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-10-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-(4-hydroxyphenyl)-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-12-9 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-(4-phenoxyphenyl)propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-18-5 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-, methyl ester, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-19-6 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[3-(4-thiazolylmethoxy)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-21-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-2-[3-(4-morpholinylmethyl)phenyl]-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-23-2 CAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-26-5 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[[3-(aminocarbonyl)phenyl]methyl]-4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-29-8 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-methyl-1-oxo-2-(4-phenoxyphenyl)propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-37-8 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-[2-(4-pyridinyl)ethenyl]phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 897395-38-9 CAPLUS
CN Benzeneacetamide, N-[5-(aminosulfonyl)tricyclo[3.3.1.13,7]dec-2-yl]-4-chloro-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-39-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-43-6 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-44-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-methyl-1-oxo-2-[4-(pentyloxy)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-45-8 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-methyl-1-oxo-2-[4-(4-thiazolylmethoxy)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-46-9 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-N-(5-thiazolylmethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-47-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-methyl-1-oxo-2-[4-(phenylmethoxy)phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-49-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-(4-chlorophenyl)-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-51-6 CAPLUS
CN Benzoic acid, 4-[[[[4-[(2-methyl-1-oxo-2-phenylpropyl)amino]tricyclo[3.3.1.13,7]dec-1-yl]carbonyl]amino]methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-52-7 CAPLUS
CN Benzoic acid, 3-[[[[4-[(2-methyl-1-oxo-2-phenylpropyl)amino]tricyclo[3.3.1.13,7]dec-1-yl]carbonyl]amino]methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-54-9 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-N-(4-pyridinylmethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-56-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-(2-furanylmethyl)-4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-57-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-N-(3-pyridinylmethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-58-3 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-N-(2-pyridinylmethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-59-4 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-[4-(cyclohexylmethoxy)phenyl]-2-methyl-1-oxopropyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-60-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[[2-methyl-1-oxo-2-[4-[5-(trifluoromethyl)-2-pyridinyl]phenyl]propyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 897395-62-9 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-(4-pyridinyl)phenyl]propyl]amino]-, (3R,5S)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 897394-88-6
CMF C26 H31 N3 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 897395-65-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, 4-[[2-methyl-1-oxo-2-[4-(3-pyridinyl)phenyl]propyl]amino]-, (3R,5S)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 897395-03-8
CMF C26 H31 N3 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 897394-71-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-adamantane carboxamide derivs. as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme)
RN 897394-71-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxylic acid, 4-[(2-methyl-1-oxo-2-phenylpropyl)amino]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:240654 CAPLUS Full-text
DOCUMENT NUMBER: 145:174227
TITLE: Application of vanilloid receptor agonist to prepare anti-Alzheimer's medical products
INVENTOR(S): Chen, Chunlin; Mao, Chen; Zhang, Jintao
PATENT ASSIGNEE(S): Shanghai Medicilon Inc., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 47 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1736485	A	20060222	CN 2005-10027292	20050629

PRIORITY APPLN. INFO.: CN 2005-10027292 20050629
GI



I

AB The medical application of vanilloid receptor agonist for prevention, diagnosis, detection, treatment, and research of Alzheimer's disease and its assocd. diseases is presented. The vanilloid receptor agonist is vanillin or its deriv. with the structure I where R1 = OH, alkyl, alkoxy, acyloxy, aminoalkoxy, H, NH2, or halo; R2 = alkoxy, H, OH, NH2, alkyl, aliph. amino, arom. amino, aminoalkoxy, or acyloxy; R3 = C5-23 alkyl, alkenyl, diterpenyl, Ph, adamantyl, C5-23 piperazinyl, or their substituted deriv.; n = 0-2; and X = NHCO, CONH, COO, NHCOO, NHCONH, NHCSNH, or NH(O)S(O) and/or capsaicin analogs without 4-hydroxy- 3-methoxybenzylvanillyl but contg. phenolic OH and three assumed binding sites (vanillyl, amido, and aliph. chain). The drug delivery systems (powder injection, injection, large-capacity injection, tablet, and capsule) of the vanilloid vector agonist were prepd.

IT 900150-25-6P 900150-58-5P
RL: DGN (Diagnostic use); FFD (Food or feed use); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(application of vanilloid receptor agonist to prep. anti-Alzheimer's medical products)

RN 900150-25-6 CAPLUS
CN Benzeneacetamide, N-(4,8-dimethyltricyclo[3.3.1.13,7]dec-2-yl)-4-hydroxy-3-methoxy- (9CI) (CA INDEX NAME)



RN 900150-58-5 CAPLUS
CN Benzeneacetamide, 4-(2-aminoethoxy)-N-(4,8-dimethyltricyclo[3.3.1.13,7]dec-2-yl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1042205 CAPLUS Full-text
DOCUMENT NUMBER: 143:346908
TITLE: Preparation of phenol derivatives as .beta.2 androgen receptor agonists
INVENTOR(S): Brown, Alan Daniel; Bunnage, Mark Edward; Glossop,

Paul Alan; James, Kim; Lane, Charlotte Alice Louise; Lewthwaite, Russell Andrew; Lunn, Graham; Price, David Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090287	A2	20050929	WO 2005-IB640	20050310
WO 2005090287	A3	20060216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1577291	A1	20050921	EP 2004-290725	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:
EP 2004-290725 A 20040317
US 2004-591790P P 20040727
GB 2004-25064 A 20041112

OTHER SOURCE(S): MARPAT 143:346908
GI



I



II

AB Title compds. I [(CH2)n-C(O)Q1 is meta or para; R1 and R2 independently = H or alkyl; n = 0-2; Q1 = mono- or disubstituted amine] and their pharmaceutically acceptable salts, are prepd. and disclosed as agonists of .beta.2 androgen receptor. Thus, e.g., II was prepd. by amidation of (3-{(2R)-2-[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(4-hydroxy-3- hydroxymethyl-phenyl)-ethylamino]-propyl}-phenyl)-acetic acid (prepn. given) with cycloheptylamine followed by deprotection. The agonist potency of I for the .beta.2 androgen receptor was evaluated using CHO cells and it was found that selected compds. of the invention possessed EC50 values in the range of 0.064 up to 0.874 nM. I as .beta.2 androgen receptor agonist should prove useful in the treatment of asthma, bronchitis and chronic obstructive pulmonary disease. Pharmaceutical compns. comprising I are disclosed.

IT 864153-28-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenol derivs. as .beta.2 androgen receptor agonists)

RN 864153-28-6 CAPLUS

CN Benzeneacetamide, 3-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 864153-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenol derivs. as .beta.2 androgen receptor agonists)

RN 864153-29-7 CAPLUS

CN Benzeneacetamide, 3-[(2R)-2-[[(2R)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1020452 CAPLUS Full-text
DOCUMENT NUMBER: 143:286168
TITLE: Phenylethanolamine derivatives as beta-2 agonists, their preparation and pharmaceutical compositions
PATENT ASSIGNEE(S): Pfizer Limited, UK
SOURCE: Eur. Pat. Appl., 99 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1577291	A1	20050921	EP 2004-290725	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
WO 2005090287	A2	20050929	WO 2005-IB640	20050310
WO 2005090287	A3	20060216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NL 1028559	A1	20050920	NL 2005-1028559	20050316
NL 1028559	C2	20060419		
US 2005234097	A1	20051020	US 2005-83265	20050316
PRIORITY APPLN. INFO.:			EP 2004-290725 A	20040317
			US 2004-591790P P	20040727
			GB 2004-25064 A	20041112
			US 2005-642875P P	20050110

OTHER SOURCE(S): MARPAT 143:286168
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to phenylethanolamine derivs. I, which are adrenergic .beta.2 agonists. In compds. I, the (CH2)n-C(=O)X group is in the meta or para position; R1 and R2 are independently selected from H and C1-4 alkyl; n is 0-2; and X is mono- or disubstituted amino. The invention also relates to the prepn. of I, pharmaceutical compns. contg. an effective amt. of a compd. I and optionally contg. one or more pharmaceutically acceptable excipients and/or additives, as well as to the use of the compns. for the treatment of inflammatory, allergic, and respiratory diseases. Me (R)-2-(benzyloxy)-5-(2-bromo-1- hydroxyethyl)benzoate was protected with TBDMS chloride and then underwent hydride redn. to give II. Esterification of 3-bromophenylacetic acid followed by tin-mediated coupling with isopropenyl acetate, enantioselective reductive amination with (R)-.alpha.-methylbenzylamine, and

hydrogenation resulted in the formation of III. Nucleophilic substitution of II with III followed by debenzylation, ester hydrolysis, amidation with cycloheptylamine, and desilylation gave phenylethanolamine IV. The compds. of the invention are agonists of .beta.2 receptors and show good potency with .beta.2 cAMP EC50 below 10 nM.

IT 864153-28-6P, N-2-Adamantyl-2-[3-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of phenylethanolamine derivs. as .beta.2 agonists)

RN 864153-28-6 CAPLUS

CN Benzeneacetamide, 3-[(2R)-2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 864153-29-7P, N-2-Adamantyl-2-[3-[(2R)-2-[[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]phenyl]acetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of phenylethanolamine derivs. as .beta.2 agonists)

RN 864153-29-7 CAPLUS

CN Benzeneacetamide, 3-[(2R)-2-[[(2R)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:443652 CAPLUS Full-text
DOCUMENT NUMBER: 143:133140
TITLE: Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest
AUTHOR(S): Dothager, Robin S.; Putt, Karson S.; Allen, Brittany J.; Leslie, Benjamin J.; Nesterenko, Vitaliy; Hergenrother, Paul J.
CORPORATE SOURCE: Department of Chemistry and Department of Biochemistry, Roger Adams Laboratory, University of Illinois, Urbana, IL, 61801, USA
SOURCE: Journal of the American Chemical Society (2005), 127(24), 8686-8696
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:133140

AB Late-stage malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The av. survival time for patients with such a diagnosis is 6 mo. In general, the vast majority of anticancer drugs operate through induction of cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis (M) phase of the cell cycle. Unfortunately, the same mechanisms that melanocytes possess to protect cells from DNA damage often confer resistance to drugs that derive their toxicity from S or M phase arrest. Described herein is the synthesis of a combinatorial library of potential proapoptotic agents and the subsequent identification of a class of small mols. (triphenylmethyl)amides (TPMAs), e.g. Ph3C(CH2)nCONHR (n = 0, 1; R = alkyl, aralkyl, aryl, etc.), that arrest the growth of melanoma cells in the G1 phase of the cell cycle. Several of these TPMAs are quite potent inducers of apoptotic death in melanoma cell lines (IC50 .apprx. 0.5 .mu.M), and importantly, some TPMAs are comparatively nontoxic to normal cells isolated from the bone marrow of healthy donors. Furthermore, the TPMAs were found to dramatically reduce the level of active nuclear factor .kappa.-B (NF.kappa.B) in the cell; NF.kappa.B is known to be constitutively active in melanoma, and this activity is crit. for the proliferation of melanoma cells and their evasion of apoptosis. Compds. that reduce the level of NF.kappa.B and arrest cells in the G1 phase of the cell cycle can provide insights into the biol. of melanoma and may be effective antimelanoma agents.

IT 851714-63-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial prepn. of triphenylmethylamides as agents that induce apoptosis in melanoma cells through G1 cell cycle arrest)

RN 851714-63-1 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-diphenyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:423717 CAPLUS Full-text
DOCUMENT NUMBER: 142:463355
TITLE: A preparation of combinatorial library of phenylacrylamide derivatives, useful for treatment of cancer and modulation of programmed cell death for melanoma
INVENTOR(S): Hergenrother, Paul J.; Nesterenko, Vitaliy; Putt, Karson; Allen, Brittany Joy; Dothager, Robin Shane; Leslie, Benjamin James
PATENT ASSIGNEE(S): The Board of Trustees of the University of Illinois, USA
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005044191	A2	20050519	WO 2004-US35746		20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005197511	A1	20050908	US 2004-976186		20041027
PRIORITY APPLN. INFO.:			US 2003-516556P	P	20031030
			US 2004-603246P	P	20040820
			US 2004-976186	A	20041027

OTHER SOURCE(S): MARPAT 142:463355
GI



I



II

AB The invention relates to a prepn. of combinatorial library of phenylacrylamide derivs. of formula I [wherein: R1 is H, one or more halogens, or one or more alkyl, etc.; R2 and R3 are independently H, halogen, halogenated alkyl, or alkoxy, etc.], useful for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells. For instance, phenylacrylamide II (IC50 = 61 .mu.M) was prepd. via amidation of (4-hydroxy-3-methoxyphenyl)acrylic acid by (2-hydroxy-2-phenylethyl)amine with a yield of 42%.

IT 851714-63-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of combinatorial library of phenylacrylamide derivs. useful for treatment of cancer)

RN 851714-63-1 CAPLUS

CN Benzeneacetamide, .alpha.,.alpha.-diphenyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:878302 CAPLUS Full-text

DOCUMENT NUMBER: 141:360694

TITLE: Combination therapy using an 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

INVENTOR(S): Kampen, Gita Camilla Tejlgaard; Andersen, Henrik Sune

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 297 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089416	A2	20041021	WO 2004-DK254	20040406
WO 2004089416	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615666	A2	20060118	EP 2004-725887	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522750	T2	20061005	JP 2006-504357	20040406
US 2006111348	A1	20060525	US 2005-254125	20051011

PRIORITY APPLN. INFO.:			
	DK 2003-565	A	20030411
	DK 2003-566	A	20030411
	DK 2003-567	A	20030411
	DK 2003-569	A	20030411
	DK 2003-570	A	20030411
	DK 2003-571	A	20030411
	US 2003-467284P	P	20030502
	US 2003-467362P	P	20030502
	US 2003-467363P	P	20030502
	US 2003-467437P	P	20030502
	US 2003-467453P	P	20030502
	US 2003-467800P	P	20030502
	DK 2003-776	A	20030522
	DK 2003-777	A	20030522
	US 2003-474421P	P	20030530
	US 2003-475157P	P	20030602
	DK 2003-972	A	20030627
	DK 2003-988	A	20030630
	DK 2003-989	A	20030630
	DK 2003-990	A	20030630
	DK 2003-998	A	20030702
	US 2003-486078P	P	20030710
	US 2003-486094P	P	20030710
	US 2003-486095P	P	20030710
	US 2003-486097P	P	20030710
	US 2003-486098P	P	20030710
	DK 2003-1910	A	20031222
	DK 2004-9	A	20040106
	US 2004-537099P	P	20040116
	WO 2004-DK254	W	20040406

OTHER SOURCE(S): MARPAT 141:360694

AB The invention discloses combination therapy comprising the administration of an 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

IT 352343-40-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxysteroid dehydrogenase inhibitor-antihypertensive agent combination for treatment of metabolic syndrome and related conditions)

RN 352343-40-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:878301 CAPLUS Full-text

DOCUMENT NUMBER: 141:360721

TITLE: Combination therapy using an 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to treat cancer and inflammation-associated diseases and to minimize the side effects associated with glucocorticoid receptor agonist therapy

INVENTOR(S): Kampen, Gita Camilla Tejlgaard; Andersen, Henrik Sune

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089415	A2	20041021	WO 2004-DK248	20040406
WO 2004089415	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615667	A2	20060118	EP 2004-725890	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522744	T2	20061005	JP 2006-504351	20040406
US 2006094699	A1	20060504	US 2005-246814	20051007
PRIORITY APPLN. INFO.:			DK 2003-565 A	20030411
			DK 2003-566 A	20030411
			DK 2003-568 A	20030411

DK 2003-569	A	20030411
DK 2003-570	A	20030411
DK 2003-571	A	20030411
US 2003-467284P	P	20030502
US 2003-467362P	P	20030502
US 2003-467363P	P	20030502
US 2003-467443P	P	20030502
US 2003-467453P	P	20030502
US 2003-467800P	P	20030502
DK 2003-776	A	20030522
DK 2003-778	A	20030522
US 2003-475157P	P	20030602
US 2003-475195P	P	20030602
DK 2003-972	A	20030627
DK 2003-988	A	20030630
DK 2003-989	A	20030630
DK 2003-990	A	20030630
DK 2003-998	A	20030702
US 2003-486078P	P	20030710
US 2003-486094P	P	20030710
US 2003-486095P	P	20030710
US 2003-486097P	P	20030710
US 2003-486098P	P	20030710
DK 2003-1910	A	20031222
DK 2004-9	A	20040106
US 2004-537099P	P	20040116
DK 2003-567	A	20030411
DK 2003-777	A	20030522
WO 2004-DK248	W	20040406

OTHER SOURCE(S): MARPAT 141:360721

AB The invention discloses combination therapy comprising the administration of an 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects assocd. with glucorticoid receptor agonist therapy.

IT 352343-40-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxysteroid dehydrogenase inhibitor-glucocorticoid agonist combination to treat cancer and inflammation-assocd. diseases and minimize side effects assocd. with glucocorticoid agonist therapy)

RN 352343-40-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:872724 CAPLUS Full-text

DOCUMENT NUMBER: 141:366223

TITLE: Pharmaceutical use of substituted amides as

11.beta.-hydroxysteroid dehydrogenase type 1 modulators, especially inhibitors, for treating metabolic

INVENTOR(S): Andersen, Henrik Sune; Kampen, Gita Camilla Tejlgaard; Christensen, Inge Thoger; Mogensen, John Patrick; Larsen, Annette Rosendal; Kilburn, John Paul

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089470	A2	20041021	WO 2004-DK250	20040406
WO 2004089470	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615698	A2	20060118	EP 2004-725891	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522746	T2	20061005	JP 2006-504353	20040406
US 2006111366	A1	20060525	US 2005-265794	20051011

PRIORITY APPLN. INFO.:

DK 2003-565	A	20030411
US 2003-467800P	P	20030502
DK 2003-972	A	20030627
DK 2003-988	A	20030630
DK 2003-989	A	20030630
DK 2003-990	A	20030630
DK 2003-998	A	20030702
US 2003-486078P	P	20030710
US 2003-486094P	P	20030710
US 2003-486095P	P	20030710
US 2003-486097P	P	20030710
US 2003-486098P	P	20030710
DK 2003-1910	A	20031222
DK 2004-9	A	20040106
US 2004-537099P	P	20040116
WO 2004-DK250	W	20040406

OTHER SOURCE(S): MARPAT 141:366223

GI



II



III

AB The invention is directed to the use of substituted amides of formula R3CONR1R2 (I), and their optical isomers or mixt. of optical isomers, including racemates, and tautomers, their prodrugs, pharmaceutically acceptable salts, [wherein R1 = (un)substituted cyclo/hetcyclo/aryl/hetaryl/alkyl, het/aryl, etc.; R2 = H, (un)substituted aryl/cycloalkyl/alkylcarboxy/alkyl, het/aryl; or R1NR2 = (un)substituted (un)satd. bi/tricyclic ring contg. 4-10 carbons, and 0-2 heteroatoms; R3 = (un)substituted cyclo/hetcyclo/aryl/alkyloxy/hetaryl/arylalkyl/alkyl, alkenyl, alkynyl, het/aryl] for modulating, esp. inhibiting, the activity of 11.beta.-hydroxysteroid dehydrogenase type 1 (11.beta.-HSD1) and use of their pharmaceutical compns. in the treatment, prevention, prophylaxis of a range of medical disorders where a decreased intracellular concn. of active glucocorticoid is desirable. The invention is also directed to the prepn. of certain title compds. I. For instance, acylation of 1H-benzimidazole-5-carboxylic acid with N-cyclohexyl-N-methylamine in THF in the presence of HOBT/EDAC/DIPEA gave amide II in 49% yield. Pyrazole-4-carboxamide (III) inhibited 11.beta.-HSD1 enzyme with an IC50 = 0.04 .mu.M. I are useful for treating metabolic disorders, type II diabetes, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, obesity, hypertension, diabetic late complications, neurodegenerative and psychiatric disorders and adverse effects of treatment or therapy with glucocorticoid receptor agonists.

IT 352343-40-9P, N-Adamantan-2-yl-2-(4-chlorophenyl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of substituted amides as 11.beta.-hydroxysteroid dehydrogenase type 1 modulators, esp. inhibitors, for treating metabolic disorders, type II diabetes and related diseases)

RN 352343-40-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:546468 CAPLUS Full-text
DOCUMENT NUMBER: 141:106272
TITLE: Preparation of adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
INVENTOR(S): Linders, Joannes Theodorus Maria; Willemsens, Gustaaf Henri Maria; Gilissen, Ronaldus Arnodus Hendrika Joseph; Buyck, Christophe Francis Robert Nestor; Vanhoof, Greta Constantia Peter; Van Der Veken, Louis Jozef Elisabeth; Jaroskova, Libuse
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056744	A1	20040708	WO 2002-EP14832	20021223
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2508621	AA	20040708	CA 2003-2508621	20031216
WO 2004056745	A2	20040708	WO 2003-EP51021	20031216
WO 2004056745	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003299243	A1	20040714	AU 2003-299243	20031216
EP 1581476	A2	20051005	EP 2003-799577	20031216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017716	A	20051122	BR 2003-17716	20031216
CN 1729158	A	20060201	CN 2003-80107278	20031216
JP 2006511570	T2	20060406	JP 2004-561497	20031216
US 2006079506	A1	20060413	US 2005-540616	20050623
NO 2005003596	A	20050722	NO 2005-3596	20050722
PRIORITY APPLN. INFO.:			WO 2002-EP14832 A	20021223
			WO 2003-EP51021 W	20031216

OTHER SOURCE(S): MARPAT 141:106272
GI



I



II

AB The title compds. I [n = 0-2; m = 0-1; R1, R2 = independently H, C1-4alkyl, (substituted)amino, C1-4alkyloxy, or R1 and R2 taken together with the carbon atom with which they are attached form a C3-6cycloalkyl or when n = 2, either R1 or R2 may be absent to form an unsatd. bond; R3 = a C6-12cycloalkyl, preferably selected from cyclo-octanyl and cyclohexyl, etc.; R4 = H or C1-C4alkyl; Q = (substituted)C3-8cycloalkyl, (substituted)heterocycle or (substituted)carbocyclic; L = (substituted)C1-c4alkyl] were prepd. as hydroxysteroid dehydrogenase inhibitors for the treatment of diseases, such as obesity, diabetes, dementia, etc. For example, reaction of 2,2-dimethyl-(4-chlorophenyl)acetic acid and 2-aminoadamantane hydrochloride furnished compd. II. The latter inhibited 11.beta.-hydroxysteroid dehydrogenase type 1 and type 2 (11.beta.-HSD1 and 11.beta.-HSD2) activities with pIC50 in the range of 5-6 and <5, resp.

IT 717889-77-5P 717889-82-2P 717889-86-6P
717889-89-9P 717889-90-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Prepn. of adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors)

RN 717889-77-5 CAPLUS

CN Benzeneacetamide, 4-chloro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-82-2 CAPLUS

CN Benzeneacetamide, 3-methoxy-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-86-6 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-
.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717889-89-9 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-spiro[1,3-dioxolane-2,2'-
tricyclo[3.3.1.13,7]decan]-6'-yl- (9CI) (CA INDEX NAME)



RN 717889-90-2 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-(6-oxotricyclo[3.3.1.13,7]dec-
2-yl)- (9CI) (CA INDEX NAME)



IT 405076-60-0P 433942-93-9P 717889-79-7P
717889-81-1P 717889-83-3P 717889-84-4P
717889-85-5P 717889-87-7P 717889-88-8P
717889-91-3P 717889-96-8P 717889-99-1P

717890-00-1P 717890-02-3P 717890-04-5P
717890-05-6P 717890-06-7P 717890-07-8P
717890-12-5P 717890-13-6P 717890-15-8P
717890-16-9P 717890-18-1P 717890-19-2P
717890-20-5P 717890-21-6P 717890-22-7P
717890-23-8P 717890-24-9P 717890-25-0P
717890-26-1P 717890-27-2P 717890-28-3P
717890-29-4P 717890-30-7P 717890-31-8P
717890-32-9P 717890-38-5P 717890-39-6P
717890-45-4P 717890-46-5P 717890-47-6P
717890-48-7P 717890-50-1P 717890-51-2P
717890-52-3P 717890-53-4P 717890-54-5P
717890-55-6P 717890-57-8P 718599-62-3P
718599-63-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Prepn. of adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors)

RN 405076-60-0 CAPLUS
CN Benzeneacetamide, N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 433942-93-9 CAPLUS
CN Benzeneacetamide, .alpha.-ethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-79-7 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-81-1 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.,3,5-tetramethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-83-3 CAPLUS
CN Benzeneacetamide, 3-hydroxy-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-84-4 CAPLUS
CN Acetic acid, [3-[1,1-dimethyl-2-oxo-2-(tricyclo[3.3.1.13,7]dec-2-ylamino)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 717889-85-5 CAPLUS
CN Benzeneacetamide, 3-[2-(dimethylamino)ethoxy]-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-87-7 CAPLUS
CN Benzeneacetamide, N-(5-fluorotricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717889-88-8 CAPLUS
CN Benzeneacetamide, N-(5-bromotricyclo[3.3.1.13,7]dec-2-yl)-3-hydroxy-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717889-91-3 CAPLUS
CN Benzeneacetamide, N-(6-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 717889-96-8 CAPLUS
CN Benzeneacetamide, .alpha.-methyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717889-99-1 CAPLUS
CN Benzeneacetamide, 4-fluoro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-00-1 CAPLUS
CN Benzeneacetamide, .alpha.-methoxy-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-02-3 CAPLUS
CN Benzeneacetamide, 4-methoxy-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-04-5 CAPLUS
CN Benzeneacetamide, .alpha.-amino-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-05-6 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-06-7 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-3-propoxy-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-07-8 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-3-[3-(1-pyrrolidinyl)propoxy]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-12-5 CAPLUS
CN Benzeneacetamide, .alpha.-methyl-4-nitro-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-13-6 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-3-[2-(1-pyrrolidinyl)ethoxy]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-15-8 CAPLUS
CN Acetic acid, [4-[1,1-dimethyl-2-oxo-2-(tricyclo[3.3.1.13,7]dec-2-ylamino)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 717890-16-9 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-4-[2-(4-morpholinyl)ethoxy]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-18-1 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-3-(methylamino)-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-19-2 CAPLUS
CN Benzeneacetamide, 3-(dimethylamino)-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-20-5 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-4-[methyl(phenylmethyl)amino]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-21-6 CAPLUS
CN Benzeneacetamide, 3-fluoro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-22-7 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 717890-23-8 CAPLUS
CN Benzeneacetamide, 3,4-dimethoxy-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-24-9 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-25-0 CAPLUS
CN Benzeneacetamide, 2,5-difluoro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-26-1 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.,3-trimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-27-2 CAPLUS
CN Benzeneacetamide, N-(1-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 717890-28-3 CAPLUS
CN Benzeneacetamide, 3-[3-(dimethylamino)propoxy]-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-29-4 CAPLUS
CN Benzeneacetamide, 2,5-dimethoxy-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-30-7 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-31-8 CAPLUS
CN Benzeneacetamide, 2,4-dichloro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-32-9 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 717890-38-5 CAPLUS
CN 1-Naphthaleneacetamide, .alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-39-6 CAPLUS
CN 2-Naphthaleneacetamide, .alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-45-4 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.,3-trimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-46-5 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-3-methoxy-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-47-6 CAPLUS
CN Benzeneacetamide, 3-hydroxy-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-48-7 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.,3,5-tetramethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-50-1 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-3-(phenylmethoxy)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-51-2 CAPLUS

CN Acetic acid, [3-[2-[(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)amino]-1,1-dimethyl-2-oxoethyl]phenoxy]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-52-3 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl-3-[2-(4-morpholinyl)ethoxy]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-53-4 CAPLUS
CN Benzeneacetamide, N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 717890-54-5 CAPLUS
CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-3-[2-(4-morpholinyl)ethoxy]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-55-6 CAPLUS

CN Benzeneacetamide, 3,5-dimethoxy-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 717890-57-8 CAPLUS
CN Benzeneacetamide, 2,6-difluoro-.alpha.,.alpha.-dimethyl-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 718599-62-3 CAPLUS
CN Benzeneacetamide, N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 718599-63-4 CAPLUS
CN Benzeneacetamide, N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-.alpha.,.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:354079 CAPLUS Full-text
DOCUMENT NUMBER: 136:355487
TITLE: Preparation of meta-benzamidine derivatives of amino acids or dipeptides as serine protease inhibitors
INVENTOR(S): Liebeschuetz, John Walter; Wylie, William Alexander; Waszkowycz, Bohdan; Murray, Christopher William; Rimmer, Andrew David; Welsh, Pauline Mary; Jones, Stuart Donald; Roscoe, Jonathan Michael Ernest; Young, Stephen Clinton; Morgan, Phillip John
PATENT ASSIGNEE(S): Tularik Ltd., UK
SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 485,678.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002055522	A1	20020509	US 2001-988082	20011119
US 6740682	B2	20040525		
WO 9911658	A1	19990311	WO 1998-GB2605	19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2000077027	A2	20001221	WO 2000-GB2291	20000613
WO 2000077027	A3	20010525		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004143018	A1	20040722	US 2004-752568	20040108

PRIORITY APPLN. INFO.:		
GB 1997-18392	A	19970829
GB 1998-3173	A	19980213
WO 1998-GB2605	W	19980828
GB 1999-13823	A	19990614
US 1999-142064P	P	19990702
US 2000-485678	A2	20000225
WO 2000-GB2291	A2	20000613
GB 1999-18741	A	19990809
GB 1999-29552	A	19991214
GB 1999-29553	A	19991214
US 2001-988082	A1	20011119

OTHER SOURCE(S): MARPAT 136:355487
GI



I

AB Title compds. I [R1, R2 = H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl; R3 = R1, R2, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulfonyl, alkylsulfenyl, alkylsulfonamido, alkylaminosulfonyl, haloalkoxy, haloalkyl; X = C, N, O, S, CO, CR1, C(R1)2, NR1 with at least one X being C, CO, CR1 or C(R1)2, with the proviso that if the benzamidine group is unsubstituted and the X-X group is -CH2C(R1)2-, then R1 = H or attached to the alkylene carbon atom by a heteroatom; L = org. linker contg. 1-5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y = N, CR1; YL = cyclic group; Cy = (un)satd., (poly)cyclic, (hetero)cyclic group optionally substituted by groups R3 or Ph optionally substituted by R3; Lp = lipophilic alkyl, heterocyclic, alkenyl, alkaryl, (poly)cycloalkyl, cycloalkenyl, aryl, aralkyl, haloalkyl, or a combination of two or more such groups optionally substituted by oxa, oxo, aza, thio, halo, amino, hydroxy or by R3; D = H bond donor group; n = 0-2], or corresponding compds. in which the (un)substituted amidino group R1R2NC(:NR1) is replaced with an (un)substituted aminomethyl group, or their physiol. tolerable salts were prepd. as serine protease inhibitors useful as antithrombotic agents. 3-Amidino- and 3-(aminomethyl)benzoyl-D-phenylglycine 4- aminomethylcyclohexylmethylamide are among 190 compds. synthesized.

IT 221235-32-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of meta-benzamidine derivs. of amino acids or dipeptides as serine protease inhibitors)

RN 221235-32-1 CAPLUS

CN Benzeneacetamide, .alpha.-[[3-(aminoiminomethyl)benzoyl]amino]-N-tricyclo[3.3.1.13,7]dec-2-yl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:184269 CAPLUS Full-text
DOCUMENT NUMBER: 130:237884
TITLE: Preparation of meta-benzamidine derivatives of amino acids or dipeptides as serine protease inhibitors

INVENTOR(S): Liebeschuetz, John Walter; Wylie, William Alexander; Waszkowycz, Bohdan; Murray, Christopher William; Rimmer, Andrew David; Welsh, Pauline Mary; Jones, Stuart Donald; Roscoe, Jonathan Michael Ernest; Young, Stephen Clinton; Morgan, Phillip John

PATENT ASSIGNEE(S): Proteus Molecular Design Ltd., UK

SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911658	A1	19990311	WO 1998-GB2605	19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9888757	A1	19990322	AU 1998-88757	19980828
EP 1009758	A1	20000621	EP 1998-940430	19980828
EP 1009758	B1	20050601		
R: DE, FR, GB, IT				
US 2002055522	A1	20020509	US 2001-988082	20011119
US 6740682	B2	20040525		
US 2004143018	A1	20040722	US 2004-752568	20040108

PRIORITY APPLN. INFO.:	GB 1997-18392	A 19970829
	GB 1998-3173	A 19980213
	WO 1998-GB2605	W 19980828
	GB 1999-13823	A 19990614
	US 1999-142064P	P 19990702
	US 2000-485678	A2 20000225
	WO 2000-GB2291	A2 20000613
	US 2001-988082	A1 20011119

OTHER SOURCE(S): MARPAT 130:237884

GI



I



II

AB Title compds. I [R1, R2 = H, OH, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl; R3 = R1, R2, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulfonyl, alkylsulfenyl, alkylsulfonamido, alkylaminosulfonyl, haloalkoxy, haloalkyl; X = C, N, O, S, CO, CR1, C(R1)2, NR1 with at least one X being C, CO, CR1 or C(R1)2, with the proviso that if the benzamidine group is unsubstituted and the X-X group is -CH2C(R1)2-, then R1 = H or attached to the alkylene carbon atom by a heteroatom; L = org. linker contg. 1-5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y = N, CR1; YL = cyclic group; Cy = (un)satd., (poly)cyclic, (hetero)cyclic group optionally substituted by groups R3 or Ph optionally substituted by R3; Lp = lipophilic alkyl, heterocyclic, alkenyl, alkaryl, (poly)cycloalkyl, cycloalkenyl, aryl, aralkyl, haloalkyl, or a combination of two or more such groups optionally substituted by oxa, oxo, aza, thio, halo, amino, hydroxy or by R3; D = H bond donor group; n = 0-2] and their physiol. tolerable salts were prepd. as serine protease inhibitors useful as antithrombotic agents. Synthesis methodol. for prepg. some I was provided, and common starting materials were Fmoc- or Boc-(D)-phenylglycine and m-amidinobenzoic acid. Descriptions of enzyme assays were given, but no enzyme inhibition data was provided for I. To measure the antithrombotic activity, a partial thromboplastin time test assay was done, and for example, m-amidinobenzoyl-D-phenylglycine ester II (prepn. not given, but 1H NMR characterization data provided), at 1.9 .mu.M concn., doubled the clotting time.

IT 221235-32-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of meta-benzamidine derivs. of amino acids or dipeptides as serine protease inhibitors)

RN 221235-32-1 CAPLUS

CN Benzeneacetamide, .alpha.-[[3-(aminoiminomethyl)benzoyl]amino]-N-tricyclo[3.3.1.13,7]dec-2-yl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:246982 CAPLUS Full-text
DOCUMENT NUMBER: 114:246982
TITLE: Preparation of arylcarboxamides for promoting formation of human nerve growth factor (NGF).
INVENTOR(S): Naruto, Shunji; Matsuda, Keiichi; Sugano, Yuichi; Sugimoto, Masahiko
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 25 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 399814	A2	19901128	EP 1990-305633	19900523
EP 399814	A3	19920108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 03086853	A2	19910411	JP 1990-119755	19900511
CA 2017287	AA	19901123	CA 1990-2017287	19900522
DD 299424	A5	19920416	DD 1990-340912	19900522
RU 2022961	C1	19941115	RU 1990-4743989	19900522
CN 1048030	A	19901226	CN 1990-103242	19900523
HU 54108	A2	19910128	HU 1990-3164	19900523
HU 208111	B	19930830		
JP 03163053	A2	19910715	JP 1990-206008	19900803
PRIORITY APPLN. INFO.:			JP 1989-129344 A	19890523
			JP 1989-204222 A	19890807

OTHER SOURCE(S): MARPAT 114:246982
GI



I



II

AB Title compds. I (R1 = H, HO-protecting group; R2 = alkyl, cycloalkyl, cycloalkyl condensed with aryl, aryl, aralkyl, heterocyclyl; R3 = H, R2; R2R3N = cyclic amino; m = 1-6; n = 1-3) and II (R1-R3 and n as before; p, y = 0-3), were prepd. for promoting NGF prodn. and secretion. 2,5-Cl2C6H3NH2 and pyridine in CH2Cl2 were treated with 3,4-(AcO)2C6H3CH2CH2COCl with ice cooling under stirring to give I [R1O)n = 3,4-(AcO)2; m = 3; R2 = 2,5-Cl2C6H3; R3 = H) (III). In a test for promotion of secretion of NGF III showed a rel. value of 201% vs. epinephrine 140%. Addnl. 95 I and II were prepd. and showed excellent activity in promoting NGF prodn. and secretion. Capsule formulations contg. 2 specific I are given.

IT 134122-91-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as promoter of human nerve growth factor formation)
RN 134122-91-1 CAPLUS
CN Benzeneacetamide, 3,4-bis(acetyloxy)-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:150442 CAPLUS Full-text
DOCUMENT NUMBER: 108:150442
TITLE: Correlation between chemical constitution and sweet taste. Malondiamides and analogs
AUTHOR(S): De Nardo, M.; Collino, F.
CORPORATE SOURCE: Ist. Chim. Farm. Tossicol., Univ. Trieste, Trieste, Italy
SOURCE: Bollettino Chimico Farmaceutico (1987), 126(3), 109-15
CODEN: BCFAAI; ISSN: 0006-6648
DOCUMENT TYPE: Journal
LANGUAGE: Italian

AB 2-Chloromalondiamide derivs. and analogs have been synthesized by reaction between chloride and substituted malondiamides and analogs in chloroform. The n-alkyl substituted derivs. are nearly all sweet-tasting; secondary amides (cyclic or not) are tasteless, but one is slightly bitter; aralkyl derivs. are bitter.

IT 113708-80-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sweetness of)
RN 113708-80-8 CAPLUS
CN Propanediamide, 2-chloro-2-phenyl-N,N'-bis(tricyclo[3.3.1.13,7]dec-2-yl)- (9CI) (CA INDEX NAME)



IT 113708-74-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., taste, and chlorination of)
RN 113708-74-0 CAPLUS
CN Propanediamide, 2-phenyl-N,N'-bis(tricyclo[3.3.1.13,7]dec-2-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:403447 CAPLUS Full-text
DOCUMENT NUMBER: 81:3447
TITLE: Synthesis of 2-aminoadamantane and its N-substituted derivatives
AUTHOR(S): Lavrova, L. N.; Klimova, N. V.; Shmar'yan, M. I.; Ul'yanova, O. V.; Vikhlyaev, Yu. I.; Skoldinov, A. P.
CORPORATE SOURCE: Inst. Farmakol., Moscow, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1974), 10(4), 761-5
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB 2-Adamantanone (I) reacted with 98% HCO2H and RR1NH [R = H, R1 = H, Me, Bu, HOCH2CH2, PhCH2, PhCH2CHMe, Ph, .gamma.-pyridyl; R = Me, R1 = Me, HOCH2CH2, PhCH(OH)CHMe; RR1N = piperidino, morpholino] in 1:2:2 ratio at reflux to give the corresponding 2-aminoadamantanes (II) in 52-96% yield; II (R = R1 = H) (III) reacted with AcCl, BzCl, and ClCH2CO2Et to give 64.7-95% II (R = H; R1 = Ac, Bz, CH2CO2Et, resp.). I reacted with HCONH2, III, and 1-aminoadamantane in HCO2H at 160-80.degree. to give II (R = H; R1 = CHO, 2- and 1-adamantyl, resp.).
IT 52917-70-1P 52917-77-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 52917-70-1 CAPLUS
CN Benzeneethanol, .beta.-methyl-.alpha.-(methyltricyclo[3.3.1.13,7]dec-2-ylamino)- (9CI) (CA INDEX NAME)



RN 52917-77-8 CAPLUS
CN Benzeneethanol, .beta.-methyl-.alpha.-(methyltricyclo[3.3.1.13,7]dec-2-ylamino)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:3518 CAPLUS Full-text

DOCUMENT NUMBER: 76:3518
TITLE: Aryl-substituted .alpha.-lactams
AUTHOR(S): Talaty, Erach R.; Utermoehlen, Clifford M.; Stekoll, Louis H.
CORPORATE SOURCE: Dep. Chem., Wichita State Univ., Wichita, KS, USA
SOURCE: Synthesis (1971), (10), 543-4
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The lactam (I, R = 2-adamantyl) (II) was prepd. and its stability compared with that of I (R = 1-adamantyl) (III). Thus, PhCH2COCl was treated with Br in boiling CCl4. The crude PhCHBrCOCl was treated with 2-aminoadamantane to give the .alpha.-bromoamide (IV). Treatment of IV with tert-BuOK in dry ether at 0.degree. yielded II. III was similarly prepd.
IT 34655-02-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 34655-02-2 CAPLUS
CN Benzeneacetamide, .alpha.-bromo-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	90.09	257.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.75	-12.75

STN INTERNATIONAL LOGOFF AT 14:40:54 ON 09 OCT 2006